3. Other Current Assets (Details Narrative) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Deferred offering costs	$ 64,783	$ 28,876
Merck Serono Agreement
Advance payments to vendors and consultants	29,203	38,938
Pharmaceutical Research Associates, Inc
Advance payments to vendors and consultants	45,365	45,365
Remaining Balance From Prior Payment To Pharmaceutical Research Associates, Inc.
Advance payments to vendors and consultants	$ 18,750	$ 31,250

Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Name:	us-gaap_OtherPrepaidExpenseCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant